Core Viewpoint - The stock price of Zhaoke Ophthalmology (06622) experienced significant volatility after reaching a peak of HKD 4.60 on August 18, 2023, marking a year-to-date increase of 283.33%. However, the stock has since entered a downward trend, with a cumulative decline of 30% over the following two and a half months, despite a recent milestone in the approval process for its key product, NVK002 [1][4][6]. Group 1: Stock Performance - Zhaoke Ophthalmology's stock price surged to a peak of HKD 4.60, reflecting a year-to-date increase of 283.33% [1] - Following the peak, the stock entered a downward trend characterized by "nine consecutive declines" and "ten consecutive declines," resulting in a cumulative drop of 30% [1] - On October 22, the stock saw a brief increase of 3.58% after the ANDA application for NVK002 was fully approved, but this gain was quickly reversed with a subsequent drop of 4.72% the following day [2][4] Group 2: Financial Performance - For the first half of 2023, Zhaoke Ophthalmology reported revenue of HKD 15.803 million, a year-on-year decline of 68.25%, and a net loss of HKD 117 million, an increase of 53.85% compared to the previous year [4] - The significant revenue drop was primarily due to a one-time licensing income of HKD 33.5 million in the previous year, which inflated the revenue base [4] - After adjusting for this one-time income, the product revenue for the current period was approximately HKD 15.1 million, showing only a slight decline from HKD 15.6 million in the same period last year [4] Group 3: Product Development and Market Potential - Zhaoke Ophthalmology's NVK002, a low-concentration atropine eye drop, has made significant progress, with its ANDA application accepted by the National Medical Products Administration of China [4][5] - The company is currently the only one in China with two concentrations of atropine eye drops under regulatory review, indicating a strong competitive position [5] - The potential market for myopia control in China is substantial, with approximately 700 million myopic patients, including 163 million children and adolescents who could benefit from NVK002 [5] - According to estimates, the myopia prevention market could reach HKD 210 billion by 2030, with a compound annual growth rate of approximately 13.7% [5] Group 4: Market Sentiment and Future Outlook - Following a significant price increase, the stock has shown signs of consolidation, with a current PB ratio of 0.92, well below the industry average of 3.15 [3] - The stock has experienced a "price flat, volume shrinking" phenomenon, indicating a potential stabilization at lower price levels [15] - Recent trading activity suggests that the stock may be nearing a bottom, with a potential for upward momentum if trading volume increases [15]
股价两个半月累跌30%，兆科眼科-B即将来到新一轮量价齐升拐点？